Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Director/PDMR Shareholding

11 Sep 2018 07:00

RNS Number : 3355A
Flying Brands Limited
11 September 2018
 

Flying Brands Limited

("Flying Brands" or the "Company")

 

PDMR Notification

 

Flying Brands, the parent company of StoneChecker® and Imaging Biometrics® focused on advanced and state of the art medical software and services, was notified on 10 September 2018 that David Smith, CEO to the Operating Subsidiaries of the Company, acquired 1,000,000 ordinary shares in the Company on 10 September 2018, representing 0.83% of the Company's issued share capital, at a price of 2.48 pence per share.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

The Directors of Flying Brands Limited accept responsibility for the contents of this announcement.

 

 **ENDS**

 

For further information please contact:

 

Flying Brands Limited

Qu Li/Trevor Brown/Vinod Kaushal

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

David Smith

2

Reason for the notification

a)

Position/status

PDMR

b)

 

Initial notification /Amendment

10 September 2018

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

 Flying Brands Limited

b)

LEI

213800SPW48XRJS2QH57

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 1p each

 

ISIN: JE00BD4H0R42

b)

Nature of the transaction

Purchase of ordinary shares

c)

Price(s) and volume(s)

1,000,000 at 2.48p per ordinary share

d)

Aggregated information

- Aggregated volume

- Price

 

 

1,000,000

2.48p

e)

Date of the transaction

10 September 2018

f)

Place of the transaction

LSE

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHSFUFASFASESU
Date   Source Headline
18th Aug 202311:20 amRNSIB & GE HealthCare Enter into Commercial Agreement
17th Aug 20237:00 amRNSHalf-year Report
19th Jul 20237:00 amRNSImaging Biometrics Installs IB Nimble™ For MCW
13th Jul 20237:00 amRNSOrphan Drug Designation for GaM in Pediatric GBM
27th Jun 20237:00 amRNSStudies Show GaM Inhibits Pediatric Tumor Growth
23rd May 202311:02 amRNSResult of AGM
23rd May 20237:00 amRNSAGM Statement
3rd May 20234:14 pmRNSNotice of AGM
26th Apr 20237:00 amRNSFinal Results
28th Feb 20233:52 pmRNSOrphan Drug Designation Status
13th Jan 20232:05 pmRNSSecond Price Monitoring Extn
13th Jan 20232:00 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
10th Jan 20237:00 amRNSLetter to Shareholders
2nd Dec 202211:11 amRNSHolding in Company
25th Oct 202211:00 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSLetter to Shareholders
26th Sep 20227:00 amRNSIssue of Warrants to Employees
16th Aug 20224:40 pmRNSSecond Price Monitoring Extn
16th Aug 20224:35 pmRNSPrice Monitoring Extension
16th Aug 20229:28 amRNSHalf-year Report
3rd Aug 20221:01 pmRNSTR1 - Notification of Major Holdings
11th Jul 20227:00 amRNSImaging Biometrics Announces Channel Partnership
31st May 202211:05 amRNSSecond Price Monitoring Extn
31st May 202211:00 amRNSPrice Monitoring Extension
31st May 20228:00 amRNSSubmission of FDA 510(k) Application for IB Zero G
30th May 202210:47 amRNSResult of AGM
5th May 20223:00 pmRNSNotice of AGM
3rd May 20222:21 pmRNSIB Broadens Quantitative Mapping
28th Apr 20225:52 pmRNSFinal Results
9th Mar 20223:08 pmRNSIQAI’s Sponsored Phase I Clinical Trial is Open
28th Feb 202211:12 amRNSTotal Voting Rights
8th Feb 20227:00 amRNSIssue of shares to Mayo Clinic
27th Jan 20227:00 amRNSImaging Biometrics LLC - Letter to Shareholders
4th Jan 20229:27 amRNSDirector/PDMR Shareholding
17th Dec 20217:37 amRNSIQ-AI Prepares for Phase I Clinical Trial Launch
13th Dec 202110:32 amRNSDirector's Interest
11th Nov 20218:52 amRNSAgreement with St. Jude Children’s Hospital
2nd Nov 20218:19 amRNSMD ANDERSON ADOPTS IB CLINIC
28th Oct 20214:00 pmRNSLetter to Shareholders
7th Oct 20214:41 pmRNSSecond Price Monitoring Extn
7th Oct 20214:36 pmRNSPrice Monitoring Extension
7th Oct 20212:05 pmRNSSecond Price Monitoring Extn
7th Oct 20212:00 pmRNSPrice Monitoring Extension
7th Oct 202112:00 pmRNSPlacing
1st Oct 20218:17 amRNSCase Report on Clinical Value of IB Software
22nd Sep 20217:00 amRNSEU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING
17th Sep 20217:00 amRNSIB Software Chosen for Accuracy and Automation
10th Sep 20217:00 amRNSUpdate on Phase I Clinical Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.